SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as investors weigh its pivot into large-scale AI and high-performance computing infrastructure, marked by a significant new Texas powered land acquisition, against ongoing skepticism regarding the timeline for securing hyperscaler tenants and potential dilution risks. The community remains sharply divided between bulls focused on the stock's long-term power capacity and potential squeeze opportunities, and bears highlighting persistent management critiques, insider selling, and high volatility compared to sector peers.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh conflicting signals from reports of limited AI chip export easing alongside broader sector concerns about infrastructure capacity and geopolitical tensions. The community is actively divided, with many debating the stock's valuation as an attractive long-term entry point versus those wary of institutional manipulation and high volatility.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently drawing significant attention as investors react to mixed signals following their recent earnings report, with community members debating the stock's high valuation versus its reputation as a resilient defensive pillar. While bulls continue to point toward strong membership growth and consistent revenue as a reason to buy the dip, bears are vocal about concerns regarding unsustainable price-to-earnings multiples and cooling consumer spending patterns.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing significant investor attention driven by high trading volume, technical breakouts on key moving averages, and community speculation surrounding an upcoming housing bill. While bulls point to operational improvements and potential rate relief as catalysts, others remain skeptical, leading to active debate over whether the stock is poised for a sustained reversal or remains vulnerable to volatility.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is currently navigating significant volatility as investors monitor the long-anticipated acquisition of Warner Bros. Discovery following recent DOJ antitrust approval. While community sentiment remains divided over the deal's complex debt structure and regulatory hurdles, the upcoming UFC broadcast at the White House is being closely watched as a high-visibility test for the firm's streaming infrastructure.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT is currently surging due to a major contract award with the U.S. Department of War to support a next-generation laser weapon system, fueling community speculation about a significant defense-sector breakthrough. Investors are actively discussing the stock's potential for further momentum as it transitions into a production-oriented platform for directed energy applications.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of beverages, food, and snacks. It operates through the following business segments: PepsiCo Foods North America (PFNA), PepsiCo Beverages North America (PBNA), International Beverages Franchise (IB Franchise), Europe, Middle East and Africa (EMEA), Latin America Foods (LatAm Foods), and Asia Pacific Foods. The PFNA segment refers to the food businesses in the United States and Canada. The PBNA segment includes beverage businesses in the United States and Canada. The IB Franchise segment involves the international franchise beverage businesses, as well as the SodaStream business. The EMEA segment pertains to food businesses and beverage businesses with company-owned bottlers in Europe, the Middle East, and Africa. The LatAm Foods segment consists of food businesses in Latin America. The Asia Pacific Foods segment is associated in food businesses in Asia Pacific, including China, Australia and New Zealand, as well as India. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.

PepsiCo Inc

PepsiCo is trending following mixed Q1 earnings that beat top and bottom-line estimates but highlighted a persistent demand gap in the North American beverage sector. The community is focused on the impact of price cuts on snack volume recovery, ongoing debates regarding PepsiCo's influence over the distribution of energy drink partners, and a valuation divergence compared to other consumer staples.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is trending as investors react to the company's aggressive pivot toward internal AI development to reduce reliance on major enterprise software vendors. While the community remains divided over the feasibility of this cost-cutting strategy and its impact on service quality, the news has sparked significant volatility across the software and consumer retail sectors.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened community interest driven by speculation over a potential short squeeze, as traders point to high short interest and rising borrow fees as catalysts for a violent move upward. Investors are actively debating the company's technical setup and pending acquisition developments while looking for a sustained break above key resistance levels to ignite a broader rally.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is currently experiencing high volatility driven by conflicting weather forecast models and uncertainty regarding potential supply disruptions in the Middle East. The community is actively debating the impact of the stock's upcoming reverse split, the sustainability of recent price swings, and whether technical patterns signal a genuine breakout or another bull trap in a sector notorious for decay.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ALT BIC vs $AKERO, $ETNB , $MTSR , $MDGL , $VKTX - AI read and NITs will be the standard and $ALT is leading. 
 
KOLs are not wrong when they say biopsy can miss or misclassify disease.  
1️⃣ Sampling error (the biggest problem) 
 
A biopsy samples ~1/50,000 of the liver 
 
Fibrosis and inflammation are heterogeneous 
 
One core can show F2, another F3 or F1 in the same patient 
 
Studies show: 
 
20–30% discordance in fibrosis staging between two biopsy samples from the same liver 
 
Inter-reader variability even among expert pathologists 
 
👉 This means biopsy can both overestimate and underestimate response. 
 
2️⃣ Noise overwhelms signal in short trials 
 
Fibrosis remodeling is slow 
 
24–52 weeks is often borderline too short to see clean stage shifts 
 
A true biological improvement may not cross the ≥1-stage threshold because of: 
 
Baseline misclassification 
 
Borderline staging 
 
Patchy regression 
 
This is why KOLs often say: 
 
“The drug worked, but the biopsy couldn’t see it.”

Patrick R.

Lynxtail

Charlie gomes

Peter Quick

No Control

Chop1182

Rajesh

Jamee's Man

StockTwits Web

Altimmune Inc

89bio Inc

Metsera Inc

Madrigal Pharmaceuticals Inc

Viking Therapeutics Inc

 - AI read and NITs will be the standard and 

 is leading. 
 
KOLs are not wrong when they say biopsy can miss or misclassify disease.  
1️⃣ Sampling error (the biggest problem) 
 
A biopsy samples ~1/50,000 of the liver 
 
Fibrosis and inflammation are heterogeneous 
 
One core can show F2, another F3 or F1 in the same patient 
 
Studies show: 
 
20–30% discordance in fibrosis staging between two biopsy samples from the same liver 
 
Inter-reader variability even among expert pathologists 
 
👉 This means biopsy can both overestimate and underestimate response. 
 
2️⃣ Noise overwhelms signal in short trials 
 
Fibrosis remodeling is slow 
 
24–52 weeks is often borderline too short to see clean stage shifts 
 
A true biological improvement may not cross the ≥1-stage threshold because of: 
 
Baseline misclassification 
 
Borderline staging 
 
Patchy regression 
 
This is why KOLs often say: 
 
“The drug worked, but the biopsy couldn’t see it.”

The Patient One

2 -  
3️⃣ Biopsy is binary, biology is continuous 
 
Biopsy forces: 
 
Continuous biology → discrete buckets (F2 vs F3) 
 
Which amplifies noise near cutoffs 
 
NITs (ELF, LSM, cT1): 
 
Capture continuous change 
 
Track trajectory 
 
Often detect improvement earlier than biopsy 
 
This is exactly why KOLs increasingly trust NIT trends clinically.

3- 
So why does biopsy still matter if KOLs distrust it? 
 
Here’s the uncomfortable truth: 
 
👉 Regulators don’t require biopsy because it’s perfect — they require it because it’s the least imperfect common standard we’ve historically had. 
 
Biopsy persists because: 
 
It is direct tissue evidence 
 
It has decades of outcome correlation 
 
It allows binary regulatory decisions 
 
There is no single NIT yet validated to replace it globally 
 
Regulation is conservative by design. It lags science. 
 
Why KOLs and regulators are talking past each other 
 
KOLs are asking: 
 
“Which tool best reflects true disease biology?” 
 
Regulators are asking: 
 
“Which tool can we defend in court, across regions, consistently, today?” 
 
Those are different questions. 
 
This is why the EMA is moving faster than the FDA 
 
European regulators are increasingly saying: 
 
“If multiple NITs move together” 
 
“If changes are large and durable” 
 
“If biology is coherent”

4- 
Then: 
 
Biopsy may not be required upfront 
 
Or can be deferred/post-approval 
 
KOL influence is absolutely shaping this shift. 
 
But we’re in a transition period, not the end state. 
 
Why this actually strengthens Altimmune’s position (important) 
 
Altimmune’s 48-week data does something biopsy often fails to do: 
 
Shows consistent improvement across multiple orthogonal NITs 
 
Shows durability 
 
Shows dose response 
 
Shows metabolic + liver coherence 
 
That is exactly the pattern KOLs say: 
 
“This is real biology, not noise.” 
 
So scientifically: 
 
ALT’s data is very strong 
 
Regulatorily: 
 
The system hasn’t fully caught up yet

5- 
Markets don’t use biopsy because it’s right — they use it because: 
Deals 
Approvals 
So histology remains the financial clearing mechanism, even as its scientific authority erodes. 
That’s the paradox you’re sensing — and you’re correct to question it. 
Where this is heading (and KOLs agree on this) 
The consensus direction is: 
Short term (now): 
Biopsy + NITs 
Medium term: 
Composite NIT endpoints accepted (especially EMA) 
Long term: 
Biopsy largely phased out except in edge cases 
We are mid-transition, not post-transition. 
Bottom line (this is the clean resolution) 
You are correct: 
Biopsy can miss real effects 
Biopsy can be wrong 
KOLs increasingly trust NITs more 
But: 
Regulation and markets still price biopsy 
Until NITs are formally elevated to surrogate status globally 
So when histology enters valuation discussions, it’s not because it’s scientifically superior — 
it’s because it’s institutionally entrenched. 
 
Altimmune’s data aligns with where medicine is going, not where regulation fully is yet.